Epoetin beta is a 165-aa glycoprotein manufactured by using recombinant DNA technology, which contains the identical amino acid sequence of isolated human EPO and possesses the same biological activity. It is similar to the endogenous EPO except for minor differences in the pattern of 4 carbohydrate chains. [Brine 2000] The recombinant human EPO has been widely used for treating anaemia associated with chronic renal insufficiency, HIV infection, cancer, and surgery, and has an excellent safety record in wide clinical practice.